RJFSA
ZVRA icon

Raymond James Financial Services Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$179K Sell
25,818
-6,135
-19% -$41.6K ﹤0.01% 3213
2024
Q2 		$157K Buy
31,953
+6,197
+24% +$29.4K ﹤0.01% 3177
2024
Q1 		$149K Sell
25,756
-100
-0.4% -$615 ﹤0.01% 3161
2023
Q4 		$169K Sell
25,856
-372
-1% -$1.74K ﹤0.01% 3037
2023
Q3 		$126K Sell
26,228
-100
-0.4% -$499 ﹤0.01% 3030
2023
Q2 		$134K Hold
26,328
– – ﹤0.01% 3017
2023
Q1 		$145K Buy
26,328
+3,798
+17% +$20.1K ﹤0.01% 2992
2022
Q4 		$103K Hold
22,530
– – ﹤0.01% 3006
2022
Q3 		$141K Hold
22,530
– – ﹤0.01% 2941
2022
Q2 		$100K Buy
22,530
+700
+3% +$3.19K ﹤0.01% 3016
2022
Q1 		$110K Sell
21,830
-100
-0.5% -$636 ﹤0.01% 3100
2021
Q4 		$191K Buy
21,930
+300
+1% +$2.68K ﹤0.01% 2989
2021
Q3 		$202K Sell
21,630
-320
-1% -$3.23K ﹤0.01% 2978
2021
Q2 		$281K Sell
21,950
-325
-1% -$3.49K ﹤0.01% 2770
2021
Q1 		$205K Buy
+22,275
New +$195K ﹤0.01% 2892

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial Services Advisors's ZVRA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Zevra Therapeutics (ZVRA) stake by 19% in Q3 2024, selling an estimated $41.6K and leaving 25,818 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #3213.

Raymond James Financial Services Advisors first reported a position in ZVRA in Q1 2021 and has held it in 15 quarters since. The position peaked at $281K in Q2 2021. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Raymond James Financial Services Advisors held 25,818 shares of Zevra Therapeutics worth $179K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 6,135 Zevra Therapeutics shares in Q3 2024, an estimated $41.6K.
  • Zevra Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3213 holding.
  • Raymond James Financial Services Advisors first reported a position in Zevra Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Raymond James Financial Services Advisors's Zevra Therapeutics position peaked at $281K in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.